Form 4: HCA Healthcare CEO Hazen's Performance Shares Vest at 200%

HCA Healthcare CEO Samuel N. Hazen's performance share units, tied to 2023-2025 EPS goals, vested at 200% of the target.

Summary

• HCA Healthcare CEO Samuel N. Hazen reported changes in beneficial ownership of common stock.
• Hazen acquired 54,934 shares of common stock on February 10, 2026, resulting from the vesting of performance share units.
• These performance share units were granted on January 30, 2023, and were eligible to vest based on the company's cumulative earnings per share (EPS) goal for fiscal years 2023-2025.
• The company achieved 200% of the target performance, leading to the vesting of 54,934 shares (200% of the initial 27,467 units granted).
• Concurrently, 21,323 shares were disposed of at a price of $502.05 per share, likely to cover tax obligations related to the vesting.
• Following these transactions, Hazen directly owns 64,842 shares and indirectly owns 1,317,472 shares through various trusts and an LP, totaling 1,382,314 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive indicator of strong past financial performance, as the CEO's performance share units vested at the maximum 200% level due to exceeding cumulative EPS goals.

Positives

• HCA Healthcare achieved 200% of its cumulative earnings per share goal for fiscal years 2023-2025, indicating strong financial performance.
• The full vesting of performance share units at the maximum 200% level for CEO Samuel N. Hazen demonstrates successful execution against long-term incentive targets.

Negatives

• A disposition of 21,323 shares occurred, likely for tax withholding purposes, which is a standard practice for equity awards and not a discretionary sale.

Future Outlook

The filing primarily reports past performance and compensation outcomes, specifically the achievement of cumulative EPS goals for fiscal years 2023-2025, which led to the maximum vesting of performance share units. It does not provide explicit forward-looking statements or guidance regarding future financial performance or strategic initiatives.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity awards at maximum levels, as seen with HCA Healthcare's CEO, is a common indicator of strong executive performance relative to pre-set financial targets. This aligns with a trend in the healthcare industry where executive compensation is increasingly tied to measurable financial and operational outcomes, reflecting a focus on shareholder value creation. The achievement of 200% of the EPS goal suggests HCA Healthcare outperformed its internal benchmarks during the 2023-2025 period, potentially signaling robust operational efficiency and market positioning within the competitive healthcare services sector.

Comparison to Industry Standards

• StockSavvy.ai observes that achieving 200% of performance targets for executive compensation is a strong outcome, often exceeding typical industry averages for performance-based vesting. While specific comparable company data is not provided in the filing, such a high achievement rate suggests HCA Healthcare's performance during the 2023-2025 period was exceptional relative to its internal goals. For instance, many peer healthcare providers might see vesting closer to 100-150% for similar EPS-based awards, making HCA's 200% a standout result.

Related Party Transactions

• Indirect ownership through various trusts (HD Trust, 2023 GST Trust, 2023 Trust, 2024 GRAT, 2025 GRAT) and an LP are disclosed, which are considered related parties to the reporting person.

Stakeholder Impact

• Shareholders: The achievement of 200% of the EPS goal for 2023-2025 suggests strong company performance, which is generally positive for shareholder value. The CEO's increased ownership aligns his interests with shareholders.
• Management/Employees: The successful vesting of performance shares at maximum levels for the CEO could serve as a positive signal regarding the company's performance culture and incentive structures.

Key Dates

Recommendation

The maximum 200% vesting of performance share units for the CEO, based on exceeding cumulative EPS goals for 2023-2025, signals exceptional financial performance by HCA Healthcare. This strong execution against long-term targets, coupled with the CEO's increased beneficial ownership, suggests robust operational health and management alignment with shareholder interests, making the stock an attractive 'buy' for seasoned investors.

Keywords

HCA Healthcare, Samuel N Hazen, Form 4, Insider Transaction, Performance Share Units, Equity Compensation, CEO, Stock Ownership, EPS Goal, Vesting